Dishman Pharmaceuticals & Chemicals Ltd has informed BSE that the Company has completed installation of three API (Active Pharmaceutical Ingredient) Units at its Bavla facility at around cost of Rs 150 Crores as “Project Taurus”.
The last (Fourth) API facility will be dedicated for cytotoxic and cytotoxic compounds, such as Anti-Cancer Drugs. Hormones, etc. This facility will be ready for commissioning before the end of the current calendar year.
This entry was posted
on Thursday, May 8th, 2008 at 5:40 am and is filed under News.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
